[Combined bone marrow and skeletal scintigraphy in osseous and myelogenous diseases].
In 87 patients with proved diagnosis and a normal or pathologic bone scan (BS) in addition a bone marrow scan (BMS) was performed using a 99mtechnetium-labelled microcolloid. The analysis of scintigraphic findings included those obtained by other investigations shows that in these selected patients a false normal or false positive interpretation would have been resulted in 18% performing the BS only. Both methods BS and BMS were capable of diagnosing the correct stage of disease in all patients. The results indicate an augmentation of diagnostic facilities by the BMS in diseases affecting bone or bone marrow.
D000328:Adult; D001847:Bone Diseases / Q000000981:diagnostic imaging*; D001853:Bone Marrow / Q000000981:diagnostic imaging*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging; D004164:Diphosphonates; D005260:Female; D006689:Hodgkin Disease / Q000000981:diagnostic imaging; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000000981:diagnostic imaging*; D010019:Osteomyelitis / Q000000981:diagnostic imaging; D012516:Osteosarcoma / Q000000981:diagnostic imaging; D010954:Plasmacytoma / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D013667:Technetium; D013669:Technetium Tc 99m Medronate
D004164:Diphosphonates; D013667:Technetium; D013669:Technetium Tc 99m Medronate
Kombinierte Knochenmark- und Skelettszintigraphie bei ossären und myelogenen Erkrankungen.